|

Colorectal Analysis for Signature Cancer Assessment Using Delta-HLD

RECRUITINGSponsored by Epiliquid Holding, Inc
Actively Recruiting
SponsorEpiliquid Holding, Inc
Started2021-06-30
Est. completion2025-08
Eligibility
Age45 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07148297

Summary

CASCADE (Colorectal Analysis for Signature Cancer Assessment Using delta-HLD Technology) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, for the detection of colorectal cancer. Epiliquid also integrates a proprietary bioinformatic system capable of identifying, ranking, and selecting tumor-specific methylation biomarkers for different cancer types. In this study, colorectal cancer-specific biomarkers will be evaluated in blood and tissue samples using delta-HLD technology, which enables sensitive and multiplexed detection through PCR. Study results will support the validation of Epiliquid's integrated platform as a minimally invasive and accessible diagnostic solution for colorectal cancer.

Eligibility

Age: 45 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* Candidate for colonoscopy or colorectal surgery
* Willing and able to provide informed consent
* Able to provide blood and/or tissue sample before treatment or resection

Exclusion Criteria:

* Prior history of colorectal cancer
* Inflammatory bowel disease
* Known hereditary cancer syndromes (e.g., Lynch, FAP)
* Other active malignancies
* Recent chemotherapy or immunosuppressive treatment

Conditions2

CancerColo-rectal Cancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.